Annual Report and Financial Statements

The report describes the company's continued development and commercialisation of the Parsortix liquid-biopsy platform during 2020, including a full FDA De Novo submission and growth to 37 peer-reviewed publications. Group revenue was £0.8 million and the company reported a loss of £11.6 million while continuing substantial investment in research, clinical studies and laboratories. Its Corporate Responsibility Report addresses human capital, health and safety, community engagement, environmental stewardship and governance.